Energy
CIRCWIND
In a context where a growing number of Wind Turbines are reaching their End of Life, the CIRCWIND project aims...


Project dates
2021 - 2024
Website
Role of Zabala
Partner
Project led by
HIPRA SCIENTIFIC SL (HIPRA SCIENTIF)
13
Partners
5
Countries
9
M€ budget
30
Months
Since the publication of the genome sequence of SARS-CoV2, on January 11th, 2020, an endeavour of unprecedented speed and magnitude set out to develop a vaccine against the disease. An ideal SARS-CoV-2 vaccine should meet the following requirements: protect not only from severe disease but also thwart infection in all vaccinated populations, including less immunocompromised individuals, elicit long term memory immune responses after a minimal number of immunizations or booster doses, able to ramp up production to produce billions of doses.
RBDCOV will provide a vaccine that should meet the following requirements: protect not only from severe disease but also thwart infection in all vaccinated populations, including less immunocompromised individuals; elicit long term memory immune responses after a minimal number of immunizations of booster doses; able to ramp up production to produce billions of doses annually and be easily accessible for worldwide vaccination campaigns at an affordable cost and at limited time.
RBDCOV is an ambitious project that will offer a new tool to control the pandemic in the short-medium and long term. RBDCOV aims to manufacture and test the first recombinant protein-based vaccine to be licensed in Europe beyond the scope of the project. The final formulation of RBDCOV vaccine, the company’s experience in the use of highly innovative platforms for the manufacture of vaccines animal vaccine manufacturing and the strong consortium involved in the RBDCOV project will make it feasible to lay the foundation for this challenging goal.


Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.

“RBDCOV mission was generated, trying to obtain a safe and efficient vaccine against COVID in a short term by merging for the first time the knowledge and capacities of key actors internationally renowned from the field of animal and human vaccine research and development”
Laura Sesma
Team leader expert in European Programmes in the Health Area












Energy
In a context where a growing number of Wind Turbines are reaching their End of Life, the CIRCWIND project aims...
Social challenges
The IRSUS project will support European innovators and companies to reach the market by providing free business services
Industry
The aim of the FETFX project is to promote FET research among a wide range of actors through community building...

News
The Battery European Technology and Innovation Platform – a new and comprehensive meeting place for stakeholders active in the battery sector, will kick off its activities on June 25, 2019 in Brussels.

Opinion
CLUSTERING OF PROJECTS

Janire García
Leader of the Dissemination and Communication of European Projects area

Publication
IAA
A concise assessment of the draft IAA’s approach and its impact on industry, investment and competitiveness
Lo importante no es seguir avanzando, sino saber hacia dónde ir. Y nuestra tasa de éxito del 37% demuestra que en Zabala sabemos guiar a nuestros clientes.
Nuestra brújula es el cliente; nuestra misión es resolver sus problemas, guiándole para que la innovación se convierta en su clave de competitividad.
